Systemically disseminated cutaneous T
Photopheresis is a new procedure (and new word) which is derived from extra corporeal photochemotherapy with leukapheresis. Apheresis is a term that refers to the procedure of removing the different elements of blood. Thus, plasmapheresis refers to the selective removal of plasma with return of erythrocytes and leukocytes. Leuka pheresis refers to removal of buffy coat (lymphocytes, polymorphonuclear leukocytes, and monocytes) while returning most of the erythrocytes and plasma. In these proce dures lost volume is often replaced with albumin solutions. In advertent depletion of erythrocytes, platelets, and granulocytes is still unavoidable. The ultimate goal of these manipulations is to modulate the immune system with minimal toxicity but traditional pheresis techniques do this in a non-specific manner. Photopheresis attempts to also provide a non-toxic immunomodulation but with a greater degree of specificity.
Leukapheresis is useful in the symptomatic management of many leukemic condi tions. By reducing the leukocyte mass there is transient relief of microvascular sludging of leukocytes and mobilization of soft tissue deposits of leukemic cells. The role of leukapheresis is clearly palliative. This procedure has been applied to the management of the leukemic phase of cutaneous T cell lymphoma (CTCL).1,2 Typically, leuka phereses are begun at a twice or thrice weekly rate. Improvement occurs very quickly and benefits are temporary with recurrence of pretreatment signs and symptoms after leukapheresis is discontinued. Thus, adjunctive therapy is indicated to prolong the effects of apheresis in this condition.
Extracorporeal therapeutic maneuvers are attractive from at least two angles. Extracorporeal systems eliminate many of the checks and balances of the intact host which may counteract the effect desired. For example, as in the case with interleukin 2, some lymphokines have extremely short half lives when injected in the intact host .3 However, in the extracorporeal system, the same lymphokine may persist for days at levels stimulatory to exposed lymphocytes. Toxicity can also be minimized by utilizing therapies at levels otherwise toxic to the intact host with conventional delivery systems.
By limiting cytotoxic therapy to the extracorporeal phase, the host immune responses are unimpeded and the patient spared considerable side effects. human equivalent of this murine model is the modality known as photopheresis. The treatment system involves lethally damaging a portion of a patient's lymphocyte com partment followed by reinfusion of these cells. The major difference is that the lethal damage in the murine system was extracorporeal treatment with mitomycin C and in the photopheresis system the damage is from extracorporeal irradiation of 8 methoxypsoralen containing lymphocytes with ultraviolet A light. The initial treatment protocol for CTCL consisted of performing two consecutive photopheresis treatments at four week intervals. Patients in the initial study of photo pheresis for CTCL were eligible if they had erythroderma and/or circulating abnormal cells with biopsy confirmation of the diagnosis. Leukemics with lymphocyte counts >20,000/mm3 were excluded as were patients with cutaneous tumors and those with any visceral infiltration of lymphoma. No treatment other than emollients and 1%
hydrocortisone were administered during the trial. A total of 37 patients were treated for a minimum of six months. Treatments were conducted in two consecutive daily sessions once monthly for six consecutive months. At that point patients were either continued on the same schedule if they were improving or they were accelerated to once weekly treatment sessions. When this regimen was followed it was found that 27 of 37 patients exhibited improvement. Of these, 29 were erythrodermic and 24 achieved The clinical response of the disease was consistent at the different centers that participated. The subset of CTCL which had the most dramatic remission rate was that of the erythrodermic stage with leukocyte counts under 15,000. The patient pre sented in Figures 2 and 3 was a member of this subset. The clearing typically occurs in a cephalocaudad progression. As the erythroderma cleared, the patients noticed a return of body hair and the capacity for eccrine sweating. Temperature intolerance and rigors tended to resolve with early signs of improvement. Discrete papules formed (or at least they were unmasked) in areas that were once erythrodermic. Histologically, these discrete papules often showed more diagnostic changes than did lesions existing prior to photopheresis. Another subset of patients had discrete plaques in conjunction with circulating abnormal cells. In this population there were a total of 8 subjects. Over the course of the protocol, 3 of these patients exhibited improvement (Fig. 3) . It is of interest that the circulating abnormal cell count rarely dropped during therapy for this group. There are other examples of extracorporeal immunomodulation appearing now also. The use of lymphokine activated killer (LAK) cells for malignancy is a similar but technically much more impractical procedure. Interleukin 2 is known to stimulate proliferation by primed lymphocytes. When administered by itself it has no remarkable clinical impact on tumors. However, if lymphocytes from cancer patients are harvested and expanded in culture with interleukin 2 there are objective anti-tumor responses.3,8 During the irradiation phase there is very limited immediate killing of lymphocytes.
However, the lymphocytes in the extracorporeal phase are severely damaged by photo pheresis. When irradiated and nonirradiated controls are compared in lymphocyte stimulation assays (phytohemaglutinin) there is a profound loss of responsiveness. This suppression is extremely dependent on the hematocrit of the leukapheresis sample (Fig. 6) . Lymphocytes respond to PHA by producing IL-2. When lymphocytes are studied for production of IL-2 in response to PHA, there is a marked deficiency of this in lymphocytes drawn from the photopheresis sample at the end of irradiation compared to controls drawn at the start of irradiation.9
Fig. 6 When PHA responsiveness is plotted against leukapheresis simple hematocrit it is apparent that the higher the hemato crit, the less suppression of responsiveness. This is felt to represent shielding of the lymphocytes by erythrocytes. Table 1 When lymphocyte subsets are analyzed after 3 days of culture, it can be seen that even though the overall population has decreased (Fig. 8) there is no selectivity detected by subset analysis. Numbers are percentages.
When irradiated lymphocytes are then placed in tissue culture there is an acceler ated decay that is proportional to the amount of light delivered (Fig. 7) , with most lymphocytes dying over a several day period. Selectivity of killing was studied by examining lymphocyte subsets before and after in vitro culturing for 72hours.
The irradiated cells still alive at this time had the same helper: suppressor ratio as did those not irradiated and controls (Table 1) . Thus the psoralen and UVA is not selec tively toxic to helper T cells in the photopheresis system. Thus, the acute effects of photopheresis on the irradiated specimen are generalized lymphocyte slow death and rapid impairment of T cell function.
The acute and chronic host responses to reinfusion of photopheresed material are less easily dissected in vivo. Lymphocyte surface markers can be utilized to demon strate an immediate decrease in circulating T cells within 24hours of a photopheresis treatment ( Table 2 ). This may represent removal by the spleen, loss of markers by internalization, loss of markers by shedding, sequestration in the skin, or acute T cell toxicity. Over months, there is a small increase in the fraction of suppressor cells (Table 3) . Since these findings are not seen in in vitro short term culture of treated cells it is apparent that the a host response has been invoked against cells not impacted The killing of cells appears to be a crucial event. Although there appears to be no selectivity to the killing, it is noteworthy that those clones expanded in a disease process would be damaged to a greater degree than resting clones by several orders of magnitude. The killing of cells may also be an avenue of potentiating this form of therapy with adjunctive agents. Should the affected cells be more susceptible during various points of the cell cycle, adjunctive therapy to synchronize cells, arrest them in the appropriate point of the cell cycle, or to inhibit DNA repair could be synergistic with this therapy. 
